Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Core Viewpoint - Puma Biotechnology's shares have declined by 9.6% over the past month due to concerns regarding a weak revenue outlook for 2026 [1][7]. Company Overview - Puma Biotechnology's only marketed product is Nerlynx (neratinib), which is approved for treating early-stage HER2-positive breast cancer and advanced or metastatic HER2-positive breast cancer [2]. - Nerlynx sales accounted for the majority of Puma's revenue, with sales increasing by 4.6% year-over-year to $204.1 million in 2025 [3]. 2026 Financial Outlook - For 2026, Puma Biotechnology expects total revenues to be between $214 million and $221 million, with Nerlynx sales projected to be between $194 million and $198 million [4][7]. - The guidance indicates a cautious growth trajectory for Nerlynx, reflecting a conservative demand outlook [4]. Pipeline Developments - Puma is developing alisertib, an aurora kinase A inhibitor, in mid-stage studies for hormone receptor-positive breast cancer and small-cell lung cancer [8][9]. - Initial phase II data for alisertib is expected in Q2 2026, which could enhance the company's position in the anti-cancer drug market if successful [9]. Competitive Landscape - Puma Biotechnology relies solely on Nerlynx for revenue, raising concerns about its growth potential amid intense competition from other approved treatments like Roche's Herceptin and Novartis' Tykerb [10]. - The bearish outlook for 2026, combined with competition and potential setbacks in ongoing studies, poses challenges for the company [11].